Bristol Interstitial lung disease (B-ILD) Tissue collection
Research type
Research Study
Full title
Investigation into the use of genetic factors and biomarkers to phenotype patients with Interstitial Lung Disease (ILD): Bristol Interstitial lung disease (B-ILD) Tissue collection.
IRAS ID
215948
Contact name
Shaney Barratt
Contact email
Sponsor organisation
University of Bristol
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Interstitial Lung Disease (ILD) is the umbrella term used to describe a group of related diseases where there is progressive damage to the lung and replacement of healthy tissue with scarred (or fibrotic)tissue These diseases are often associated with severe consequences in terms of impairment of functional capacity, quality of life and increased mortality (NHS England. 2013, NICE costing report. 2013).
Biomarkers have the potential to help discriminate between health and disease. They can be used to assess disease severity, predict clinical progression or track response to therapy. Clinicians would benefit from bedside tools that would help us better understand who to treat, when to treat and which patients are likely to respond best to novel high cost drugs developed for this field.
This study aims to evaluate whether we can use biomarkers or genetic factors in the clinical setting to help inform patients of their prognosis or to direct us on which patients are most likely to benefit from existing treatments.
REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
17/LO/1403
Date of REC Opinion
16 Oct 2017
REC opinion
Further Information Favourable Opinion